The use of biologics for psoriasis in Asia-Pacific region

Current Rheumatology Reviews

Volumn 5, Issue 3, 2009, Pages 149-152

  Tsai, Tsen Fang ^a   Yeh, Ting Yu ^b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b PETERBOROUGH DISTRICT HOSPITAL   (United Kingdom)

Author keywords

Alefacept; Asian; Efalizumab; Psoriasis; Psoriatic arthritis; TNF blocker; Usterkinumab

Indexed keywords

ADALIMUMAB; ALEFACEPT; CD11 ANTIGEN; EFALIZUMAB; ETANERCEPT; INFLIXIMAB; INTERCELLULAR ADHESION MOLECULE 1; METHOTREXATE; USTEKINUMAB;

ABSENCE OF SIDE EFFECTS; ANTIGEN EXPRESSION; ARTHRALGIA; ARTHRITIS; ASIA; ASIA PACIFIC; CLINICAL TRIAL; DRUG APPROVAL; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; EUROPE; GEOGRAPHIC DISTRIBUTION; HUMAN; JAPAN; LOADING DRUG DOSE; LOW DRUG DOSE; MAINTENANCE DRUG DOSE; PHARMACOLOGICAL BLOCKING; POPULATION DIFFERENTIATION; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PRURITUS; PSORIASIS; PSORIASIS VULGARIS; REVIEW; RHEUMATOID ARTHRITIS; SOUTH KOREA; T LYMPHOBLAST; TAIWAN; TREATMENT DURATION; TREATMENT RESPONSE; UNITED STATES;

EID: 70449650390     PISSN: 15733971     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339709789208615     Document Type: Review

References (34)

1. Ferrándiz C, Bordas X, García-Patos V, et al. Prevalence of psoriasis in Spain (Epiderma Project: Phase). J Eur Acad Dermatol Venereol 2001; 15: 20-23 (Pubitemid 32842768)
2. Raychaudhuri SP, Farber EM. The prevalence of psoriasis in the world. J Eur Acad Dermatol Venereol 2001; 15: 16-17
3. Farber EM, Nail L. Epidemiology: natural history and genetics. In: Roenigk HR Jr, Maibach HI, Eds. Psoriasis, 3rd Ed. New York: Marcel Dekker 1998, pp. 107-157
4. Yip SY. The prevalence of psoriasis in the Mongoloid race. J Am Acad Dermatol 1984; 10: 965-968
5. Tsai TF. Current status and prospect for psoriasis treatment in Taiwan. Dermatol Sinica 2005; 23: 69-80.
6. Chua-Ty G, Goh CL, Koh SL. Pattern of skin diseases at the National Skin Centre (Singapore) from 1989-1990. Int J Dermatol 1989; 31: 555-559
7. Tsai TF, Hu CY, Tsai WL, et al. HLA-Cw6 specificity and polymorphic residues are associated with susceptibility among Chinese psoriatics in Taiwan. Arch Dermatol Res 2002; 294: 214-220
8. Kim TG, Lee HJ, Youn JI, et al. The association of psoriasis with human leukocyte antigens in Korean population and the influence of age of onset and sex. J Invest Dermatol 2000; 114: 309-313
9. Nakagawa H, Akazaki S, Asahina A, et al. Study of HLA class I, class II and complement genes (C2, C4A, C4B and BF) in Japanese psoriatics and analysis of a newly-found high-risk haplotype by pulsed field gel electrophoresis. Arch Dermatol Res 1991; 283: 281-284
10. Lebwohl M, Christophers E, Langley R, et al. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular aletacept in patients with chronic plaque psoriasis. Arch Dermatol 2003; 139: 719-727 (Pubitemid 36705938)
11. Ortonne JP. Clinical response to alefacept: Results of a phase 3 study of intramuscular administration of alefacept in patients with chronic plaque psoriasis. J Eur Acad Dermatol Venereol 2003; 17(Supp2): 12-16 (Pubitemid 36869295)
12. Ellis CN, Krueger GG. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. New Engl J Med 2001; 345: 248-255
13. Huang PH, Liao YH, Wei CC, Tseng YH, Ho JC, Tsai TF. Clinical effectiveness and safety experience with alefacept in the treatment of patients with moderate-to-severe chronic plaque psoriasis in Taiwan: Results of an open-label, single-arm, multicentre pilot study. J Eur Acad Dermatol Venereol 2008; 22, 923-930
14. Sterry W, Bagot M, Ferrandiz C, et al. Immunosuppressive therapy in dermatology and PML. J Dtsch Dermatol Ges 2009; 7: 5.
15. Tsai TF, Liu MT, Liao YH, Licu D. Clinical effectiveness and safety experience with efalizumab in the treatment of patients with moderate-to-severe plaque psoriasis in Taiwan: Results of an open-label, single-arm pilot study. J Eur Acad Dermatol Venereol 2008; 22: 345-352 (Pubitemid 351247426)
16. Lebwohl M, Tyring SK, Hamilton TK, et al. A novel targeted T-cell modulator, Efalizumab, for plaque psoriasis. N Engl J Med 2003; 349: 2004-2013 (Pubitemid 37448923)
17. Leonardi CL, Papp KA, Gordon KB, et al. Efalizumab Study Group. Extended Efalizumab therapy improves chronic plaque psoriasis: Results from a randomized phase III trial. J Am Acad Dermatol 2005; 52: 425-433
18. Pincelli C, Henninger E, Casset-Semanaz F. The incidence of arthropathy adverse events in Efalizumab-treated patients is low and similar to placebo and does not increase with long-term treatment: Pooled analysis of data from Phase III clinical trials of Efalizumab. Arch Dermatol Res 2006; 298: 329-338 (Pubitemid 44777681)
19. Saurat JH, Stingl G, Dubertret L, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008; 158: 558-566
20. Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. J Am Acad Dermatol 2008; 58: 106-115 (Pubitemid 350298146)
21. nd Annual Meeting of the Japanese Society for Psoriasis Research, Shima City, Japan, 2007, pp. 77.
22. Asahina A. Results of long-term trial of anti-human TNF-alpha monoclonal antibody in patients with psoriasis vulgaris. 107th Annual meeting of Japanese Dermatological Association, Kyoto, Japan (April 18-20, 2008).
23. th December poster 29.
24. Na JI, Kim JH, Park KC, Youn SW. Low-dose etanercept therapy in moderate to severe psoriasis in Korean. J Dermatol 2008; 35: 484-490
25. Mitshubishi Tanabe Pharm Corp. Interview form for Remicade for I.V. infusion 100 (Infliximab). Osaka: Mitsubishi Tanabe Pharma Corp., 2007. http://di.mt-pharma.co.jp/file/if/f-rec-a.pdf (accessed 2009-04-29).
26. Abe T, Takeuchi T, Miyasaka N, et al. A multicenter, double-blind, randomized, placebo controlled trial of infliximab combined with low dose methotrexate in Japanese patients with rheumatoid arthritis. J Rheumatol 2006; 33: 37-44. (Pubitemid 43054277)
27. Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric antitumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial. ATTRACT Study Group. Lancet 1999; 354: 1932-1939.
28. Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomized, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008; 371: 1665-1674 (Pubitemid 351671883)
29. Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomized, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008; 371: 1675-1684 (Pubitemid 351671884)
30. Nemoto O, Uemura K, Kawamura K, et al. Evaluation of anti-IL12/23p40 antibody in patients with psoriasis vulgaris. Proceedings of the 22nd Annual Meeting of the Japanese Society for Psoriasis Research, Shima City, Japan, 2007; pp. 74-75
31. Fan X, Yang S, Sun LD, et al. Comparison of clinical features of HLA-Cw*0602-positive and -negative psoriasis patients in a Han Chinese population. Acta Derm Venereol 2007; 87: 335-340
32. Gudjonsson JE, Karason A, Runarsdottir EH, et al. Distinct clinical differences between HLA-Cw*0602 positive and negative psoriasis patients - an analysis of 1019 HLA-C- and HLA-B-typed patients. J Invest Dermatol 2006; 126: 740-745
33. Gulliver WP. HLA-Cw6 and TNF-alpha polymorphism may help predict response to biologic therapy in patients with chronic plaque psoriasis. Canadian Dermatology association 82th Annual Conference. Toronto, Ontario. 2007.
34. Costanzo A, Talamonti, M, Mazzotta A, Papoutsaki M, Chimenti S. HLA-Cw6 allele confers sensitivity to Efalizumab treatment in psoriasis. Psoriasis. From Gene to Clinic, 5th International Congress. London, U.K., December 4-6, 2008.